Video

Medicare Part D and Oncology

Author(s):

Lauren Santye, Assistant Editor

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Marc O'Connor, COO and chief strategy officer at Curant Health, discusses how the shift to Medicare Part D could impact patients undergoing treatment for cancer.

Related Videos
California Wildfires, Pharmacies, Community | image Credit: J Bettencourt/peopleimages.com | stock.adobe.com
California Wildfire, Pharmacy, Community | Image Credit: Erin | stock.adobe.com
Allergies, Asthma, Biologic Treatment, Pharmacists | Image Credit: Pixel-Shot | stock.adobe.com
Related Content
FDA headquarters -- Image credit: Tada Images | stock.adobe.com
Published: January 23rd 2025 | Updated: January 23rd 2025

FDA Grants Approval to Generic Extended-Release Memantine/Donepezil and Everolimus

Gillian McGovern, Associate Editor
Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting
December 23rd 2024

Pharmacy Focus: Oncology Edition – Key Insights and Interviews From the 2024 SABCS Meeting

Alexandra Gerlach, Associate Editor
Cholesterol plague in artery -- Image credit: Rasi | stock.adobe.com
January 23rd 2025

Potential Safety Concerns With Evinacumab

Jordan Krumanocker, PharmD, CPP, BCACP Geena Eglin, PharmD, BCACP, CSP, CPP
Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments
November 25th 2024

Pharmacy Focus: Oncology Edition - Discussing Increasing Rates of Lung Cancer in Young Adults and Emerging Precision Treatments

Blast cell in Acute myeloid leukemia from human blood cells (White blood cells cancer , Bone marrow aspirate)
January 22nd 2025

FDA Approves Treosulfan Regimen For Preparative Use in Stem Cell Transplantation Patients With AML, MDS

Luke Halpern, Assistant Editor
cropped view of dermatologist in latex gloves holding dermatoscope while examining patient with skin disease - Image credit: LIGHTFIELD STUDIOS | stock.adobe.com
January 22nd 2025

FDA Gives Priority Review to Vusolimogene Oderparepvec for Melanoma

Kennedy Ferruggia, Assistant Editor